EGFR and prostate cancer: Taking advantage of high‐throughput screening approaches and using models of PCa cells mimicking early (PNT2‐ETV1 and PNT2‐ERG) and advanced (LNCaP and VCaP) prostate cancer, we gained better insights into the relevance of the EGFR/STATs pathway for ETS‐driven prostate carcinogenesis.